Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized Comparison of the Efficacy and Safety of Intramuscular Olanzapine and Intramuscular Haloperidol in Acutely Agitated Patients With Schizophrenia

NCT00485901 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00485901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized Comparison of the Efficacy and Safety of Intramuscular Olanzapine and Intramuscular Haloperidol in Acutely Agitated Patients With Schizophrenia
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2004
Completion date
January 31, 2005
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia